Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) is a Healthcare company (Biotechnology) with a market capitalization of $973M. The Maz Rating grades it against the other companies in its sector.
Seaport Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $18.17, Seaport Therapeutics, Inc. Common Stock trades at 2.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -59.1%, return on invested capital of -37.5% and a free cash flow yield of -9.8%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 17.48. Over the past 52 weeks the share price ranged from $14.85 to $28.38, with a beta of 1.13.
Seaport Therapeutics, Inc. Common Stock does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Seaport Therapeutics, Inc. Common Stock (SPTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.14% / 30% · (Cash+Inv) / Mkt Cap (36m) 35.5% / 30% · Interest income / Revenue 390000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.14% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 25.6% / 33% · Receivables / Mkt Cap (36m) 0.42% / 49% · Interest income / Revenue 390000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.14% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 25.6% / 33.33% · Receivables / Mkt Cap (24m) 0.42% / 33.33% · Interest income / Revenue 390000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.36% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 72.0% / 33.33% · Receivables / Avg Assets (4Q) 1.19% / 33.33% · Interest income / Revenue 390000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.39% / 33.33% · (Cash+ST Inv) / Total Assets 69.5% / 33.33% · (Cash+Recv) / Total Assets 70.7% / 33.33% · Interest income / Revenue 390000000.0% / 5% | Fail |
No. As of September 2026, Seaport Therapeutics, Inc. Common Stock (SPTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Seaport Therapeutics, Inc. Common Stock is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 390000000.0% of each dividend: Seaport Therapeutics, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.